Research programme: antibody therapeutics - L.E.A.F. Pharmaceuticals

Drug Profile

Research programme: antibody therapeutics - L.E.A.F. Pharmaceuticals

Alternative Names: LEAF-161B8; LEAF-162H9; LEAF-166D1-25-10; LEAF-167E1; LEAF-169B10; LEAF-169G5; LEAF-169G5-19-19

Latest Information Update: 18 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator L.E.A.F. Pharmaceuticals
  • Class Antibodies; Antineoplastics; Immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Autoimmune disorders; Cancer

Most Recent Events

  • 18 Aug 2017 Preclinical trials in Autoimmune disorders in USA (unspecified route) (L.E.A.F. Pharmaceuticals pipeline, August 2017) prior to August 2017
  • 18 Aug 2017 Preclinical trials in Cancer in USA (unspecified route) (L.E.A.F. Pharmaceuticals pipeline, August 2017) prior to August 2017
  • 16 Aug 2017 L.E.A.F. Pharmaceuticals has patents pending related to its intellectual property
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top